Is JetBlue The Best Airline Stock?
Following a general trend of improvement among airline stocks, shares…
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
GLPGF
Galapagos NV
|
$80.4M | -- | -0.12% | -- | -- |
|
CLYYF
Celyad Oncology SA
|
-- | -- | -- | -- | -- |
|
MDXH
MDxHealth SA
|
$28M | -$0.26 | 23% | -35.9% | $7.0400 |
|
NYXH
Nyxoah SA
|
$2.3M | -$0.65 | 198.31% | -26.1% | $11.23 |
|
UCBJY
UCB SA
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
GLPGF
Galapagos NV
|
$31.29 | -- | $2.1B | 18.70x | $0.00 | 0% | 6.51x |
|
CLYYF
Celyad Oncology SA
|
$0.18 | -- | $7.5M | -- | $0.00 | 0% | 37.01x |
|
MDXH
MDxHealth SA
|
$3.3500 | $7.0400 | $165.8M | -- | $0.00 | 0% | 1.60x |
|
NYXH
Nyxoah SA
|
$4.87 | $11.23 | $209.5M | -- | $0.00 | 0% | 28.90x |
|
UCBJY
UCB SA
|
$140.78 | -- | $53.5B | 37.83x | $0.79 | 0.56% | 7.35x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
GLPGF
Galapagos NV
|
0.31% | 0.871 | 0.4% | 8.44x |
|
CLYYF
Celyad Oncology SA
|
-- | 0.910 | -- | -- |
|
MDXH
MDxHealth SA
|
110.38% | 2.496 | 38.19% | 0.98x |
|
NYXH
Nyxoah SA
|
29.34% | 3.060 | 14.4% | 1.22x |
|
UCBJY
UCB SA
|
21.7% | 0.945 | -- | 1.00x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
GLPGF
Galapagos NV
|
$70.5M | -$56.2M | -16.42% | -16.48% | -67.61% | -$65.2M |
|
CLYYF
Celyad Oncology SA
|
-- | -- | -- | -- | -- | -- |
|
MDXH
MDxHealth SA
|
$16.6M | -$3.5M | -39.3% | -548.42% | -12.67% | -$1M |
|
NYXH
Nyxoah SA
|
-$288.6K | -$28.5M | -76.64% | -96.48% | -1238.32% | -$25M |
|
UCBJY
UCB SA
|
-- | -- | 10.75% | 13.88% | -- | -- |
Celyad Oncology SA has a net margin of -286.67% compared to Galapagos NV's net margin of --. Galapagos NV's return on equity of -16.48% beat Celyad Oncology SA's return on equity of --.
| Company | Gross Margin | Earnings Per Share | Invested Capital |
|---|---|---|---|
|
GLPGF
Galapagos NV
|
84.76% | -$3.58 | $2.9B |
|
CLYYF
Celyad Oncology SA
|
-- | -- | -- |
Galapagos NV has a consensus price target of --, signalling downside risk potential of --. On the other hand Celyad Oncology SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Galapagos NV has higher upside potential than Celyad Oncology SA, analysts believe Galapagos NV is more attractive than Celyad Oncology SA.
| Company | Buy Ratings | Hold Ratings | Sell Ratings |
|---|---|---|---|
|
GLPGF
Galapagos NV
|
0 | 0 | 0 |
|
CLYYF
Celyad Oncology SA
|
0 | 0 | 0 |
Galapagos NV has a beta of 0.409, which suggesting that the stock is 59.063% less volatile than S&P 500. In comparison Celyad Oncology SA has a beta of 0.162, suggesting its less volatile than the S&P 500 by 83.796%.
Galapagos NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Celyad Oncology SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galapagos NV pays -- of its earnings as a dividend. Celyad Oncology SA pays out -- of its earnings as a dividend.
Galapagos NV quarterly revenues are $83.2M, which are larger than Celyad Oncology SA quarterly revenues of --. Galapagos NV's net income of -$238.4M is higher than Celyad Oncology SA's net income of --. Notably, Galapagos NV's price-to-earnings ratio is 18.70x while Celyad Oncology SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galapagos NV is 6.51x versus 37.01x for Celyad Oncology SA. Usually stocks with elevated PS ratios are considered overvalued.
| Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
|---|---|---|---|---|
|
GLPGF
Galapagos NV
|
6.51x | 18.70x | $83.2M | -$238.4M |
|
CLYYF
Celyad Oncology SA
|
37.01x | -- | -- | -- |
MDxHealth SA has a net margin of -286.67% compared to Galapagos NV's net margin of -29.2%. Galapagos NV's return on equity of -16.48% beat MDxHealth SA's return on equity of -548.42%.
| Company | Gross Margin | Earnings Per Share | Invested Capital |
|---|---|---|---|
|
GLPGF
Galapagos NV
|
84.76% | -$3.58 | $2.9B |
|
MDXH
MDxHealth SA
|
60.43% | -$0.16 | $79.6M |
Galapagos NV has a consensus price target of --, signalling downside risk potential of --. On the other hand MDxHealth SA has an analysts' consensus of $7.0400 which suggests that it could grow by 110.15%. Given that MDxHealth SA has higher upside potential than Galapagos NV, analysts believe MDxHealth SA is more attractive than Galapagos NV.
| Company | Buy Ratings | Hold Ratings | Sell Ratings |
|---|---|---|---|
|
GLPGF
Galapagos NV
|
0 | 0 | 0 |
|
MDXH
MDxHealth SA
|
6 | 0 | 0 |
Galapagos NV has a beta of 0.409, which suggesting that the stock is 59.063% less volatile than S&P 500. In comparison MDxHealth SA has a beta of -557,066.812, suggesting its less volatile than the S&P 500 by 55706781.163%.
Galapagos NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MDxHealth SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galapagos NV pays -- of its earnings as a dividend. MDxHealth SA pays out -- of its earnings as a dividend.
Galapagos NV quarterly revenues are $83.2M, which are larger than MDxHealth SA quarterly revenues of $27.4M. Galapagos NV's net income of -$238.4M is lower than MDxHealth SA's net income of -$8M. Notably, Galapagos NV's price-to-earnings ratio is 18.70x while MDxHealth SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galapagos NV is 6.51x versus 1.60x for MDxHealth SA. Usually stocks with elevated PS ratios are considered overvalued.
| Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
|---|---|---|---|---|
|
GLPGF
Galapagos NV
|
6.51x | 18.70x | $83.2M | -$238.4M |
|
MDXH
MDxHealth SA
|
1.60x | -- | $27.4M | -$8M |
Nyxoah SA has a net margin of -286.67% compared to Galapagos NV's net margin of -1195.73%. Galapagos NV's return on equity of -16.48% beat Nyxoah SA's return on equity of -96.48%.
| Company | Gross Margin | Earnings Per Share | Invested Capital |
|---|---|---|---|
|
GLPGF
Galapagos NV
|
84.76% | -$3.58 | $2.9B |
|
NYXH
Nyxoah SA
|
-12.52% | -$0.74 | $84.7M |
Galapagos NV has a consensus price target of --, signalling downside risk potential of --. On the other hand Nyxoah SA has an analysts' consensus of $11.23 which suggests that it could grow by 130.05%. Given that Nyxoah SA has higher upside potential than Galapagos NV, analysts believe Nyxoah SA is more attractive than Galapagos NV.
| Company | Buy Ratings | Hold Ratings | Sell Ratings |
|---|---|---|---|
|
GLPGF
Galapagos NV
|
0 | 0 | 0 |
|
NYXH
Nyxoah SA
|
3 | 1 | 0 |
Galapagos NV has a beta of 0.409, which suggesting that the stock is 59.063% less volatile than S&P 500. In comparison Nyxoah SA has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
Galapagos NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nyxoah SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galapagos NV pays -- of its earnings as a dividend. Nyxoah SA pays out -- of its earnings as a dividend.
Galapagos NV quarterly revenues are $83.2M, which are larger than Nyxoah SA quarterly revenues of $2.3M. Galapagos NV's net income of -$238.4M is lower than Nyxoah SA's net income of -$27.6M. Notably, Galapagos NV's price-to-earnings ratio is 18.70x while Nyxoah SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galapagos NV is 6.51x versus 28.90x for Nyxoah SA. Usually stocks with elevated PS ratios are considered overvalued.
| Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
|---|---|---|---|---|
|
GLPGF
Galapagos NV
|
6.51x | 18.70x | $83.2M | -$238.4M |
|
NYXH
Nyxoah SA
|
28.90x | -- | $2.3M | -$27.6M |
UCB SA has a net margin of -286.67% compared to Galapagos NV's net margin of --. Galapagos NV's return on equity of -16.48% beat UCB SA's return on equity of 13.88%.
| Company | Gross Margin | Earnings Per Share | Invested Capital |
|---|---|---|---|
|
GLPGF
Galapagos NV
|
84.76% | -$3.58 | $2.9B |
|
UCBJY
UCB SA
|
-- | -- | $14.5B |
Galapagos NV has a consensus price target of --, signalling downside risk potential of --. On the other hand UCB SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Galapagos NV has higher upside potential than UCB SA, analysts believe Galapagos NV is more attractive than UCB SA.
| Company | Buy Ratings | Hold Ratings | Sell Ratings |
|---|---|---|---|
|
GLPGF
Galapagos NV
|
0 | 0 | 0 |
|
UCBJY
UCB SA
|
0 | 0 | 0 |
Galapagos NV has a beta of 0.409, which suggesting that the stock is 59.063% less volatile than S&P 500. In comparison UCB SA has a beta of 0.675, suggesting its less volatile than the S&P 500 by 32.475%.
Galapagos NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. UCB SA offers a yield of 0.56% to investors and pays a quarterly dividend of $0.79 per share. Galapagos NV pays -- of its earnings as a dividend. UCB SA pays out 15.96% of its earnings as a dividend. UCB SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
Galapagos NV quarterly revenues are $83.2M, which are larger than UCB SA quarterly revenues of --. Galapagos NV's net income of -$238.4M is higher than UCB SA's net income of --. Notably, Galapagos NV's price-to-earnings ratio is 18.70x while UCB SA's PE ratio is 37.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galapagos NV is 6.51x versus 7.35x for UCB SA. Usually stocks with elevated PS ratios are considered overvalued.
| Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
|---|---|---|---|---|
|
GLPGF
Galapagos NV
|
6.51x | 18.70x | $83.2M | -$238.4M |
|
UCBJY
UCB SA
|
7.35x | 37.83x | -- | -- |
Signup to receive the latest stock alerts
Following a general trend of improvement among airline stocks, shares…
Following a bidding war, Netflix (NASDAQ:NFLX) has announced its intention…
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Market Cap: $4.5T
P/E Ratio: 63x
Market Cap: $4.1T
P/E Ratio: 37x
Market Cap: $3.8T
P/E Ratio: 40x
Photronics, Inc. [PLAB] is up 45.35% over the past day.
Olema Pharmaceuticals, Inc. [OLMA] is up 15.35% over the past day.
Telesat Corp. [TSAT] is up 3.07% over the past day.